Clinical trial • Phase I • Infectious Disease
Isoniazid for Tuberculosis
Phase I trial of Isoniazid for Tuberculosis. 8 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- Tuberculosis
- Trial Stage
- Phase I
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 14-10-2024
- First CTIS Authorization Date
- 29-11-2024
Trial design
Phase I trial across 1 site in Netherlands.
- Target Sample Size
- 8
Recruitment
- Planned Sample Size
- 8
- Recruitment Window Months
- 24
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 8
Netherlands
- Earliest CTIS Part Ii Submission Date
- 11-11-2024
- Latest Decision Or Authorization Date
- 29-11-2024
- Processing Time Days
- 18
- Number Of Sites
- 1
- Number Of Participants
- 8
Sites
- Site Name
- UMCG
- Department Name
- Pulmonary Diseases & Tuberculosis
- Contact Person Name
- Onno Akkerman
- Contact Person Email
- o.w.akkerman@umcg.nl
Sponsor
Primary sponsor
- Full Name
- Universitair Medisch Centrum Groningen
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Investigational products
- Investigational Product Name
- Isoniazid (INH) inhalation
- Active Substance
- Isoniazid
- Modality
- Small molecule
- Routes Of Administration
- Inhalation (nebulization)
- Route
- Inhalation (nebulization)
Related trials
Other published trials that may interest you.
- Clinical trial in Tuberculosis
- Pyrazinamide for Tuberculosis
- Rifampicin for Tuberculosis
- Conditioned medium from a co-culture of M2-macrophages and fat-derived mesenchymal cells for Acute respiratory distress syndrome (ARDS) | SARS-CoV-2 infection | Influenza A infection | Influenza B infection | Respiratory syncytial virus (RSV) infection
- ACICLOVIR for Recurrent herpes labialis | Herpes simplex labialis